You are here: Industry Insights > Market News > Vivimed Labs receives $ 7.5 million fund from OrbiMed Asia

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Vivimed Labs receives $ 7.5 million fund from OrbiMed Asia

expressbpdJanuary 02, 2018

Tag: Vivimed Labs , healthcare

Favorites

The additional funds will be utilised to fuel growth opportunities

Vivimed Labs has received additional investment of $ 7.5 million (over Rs 47 crore) from healthcare investment firm OrbiMed Asia in its subsidiary Vivimed Labs (Mascarene).

The company had earlier received $ 42.5 million from OrbiMed Asia in September 2017, Vivimed Labs said in a BSE filing.

The overseas subsidiary is the holding entity of the company’s active pharmaceutical ingredient (API) business, it added.

This additional follow on investment by OrbiMed Asia reiterates the confidence of the investor in the Vivimed business model in the health care industry, Vivimed Labs MD Santosh Varalwar said.

"The additional funds will fuel its growth opportunities overall," he added.

Previous:Mylan-Biocon’s breast cancer biosimilar gets ANVISA nod

Next:Some of FDA’s Major Policy Goals For 2018

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Vivimed Labs receives $ 7.5 million fund from OrbiMed Asia | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Nutritional Healthcare Supplement OEM private label Enzyme Juice Prices Fresh Noni Fruit Powder

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 50ml

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap

White PE HDPE PP Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 2

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 180ml

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 40ml

1%-10% Withanolide Ashwagandha Extract for Healthcare Products

Healthcare Products Chaga Mushroom Extract /Chaga polysaccharide

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 70ml

Pet Plastic Amber Solid Pill Bottle Healthcare Supplement Container Withscrew Cap 250ml

Vivimed Labs receives $ 7.5 million fund from OrbiMed Asia

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>